Coherus Bio (NQ: CHRS )
6.000 +0.100 (+1.69%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
All News about Coherus Bio
Coherus BioSciences's Return On Capital Employed Overview
March 09, 2023
FDA Approves UDENYCA® Autoinjector
March 06, 2023
A Preview Of Coherus BioSciences's Earnings
March 03, 2023
Looking Into Coherus BioSciences Return On Capital Employed
August 17, 2022
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
February 18, 2023
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...
Via Talk Markets
Coherus BioSciences Announces New Employment Inducement Grants
February 03, 2023
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 15, 2023
Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
December 23, 2022
Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer...
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical
October 12, 2022
Coherus BioSciences (NASDAQ: CHRS) announced that the United States Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Toripalimab in...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following